Eltanexor Effectively Reduces Viability of Glioblastoma and Glioblastoma Stem-Like Cells at Nano-Molar Concentrations and Sensitizes to Radiotherapy and Temozolomide

Current standard adjuvant therapy of glioblastoma multiforme (GBM) using temozolomide (TMZ) frequently fails due to therapy resistance. Thus, novel therapeutic approaches are highly demanded. We tested the therapeutic efficacy of the second-generation XPO1 inhibitor Eltanexor using assays for cell v...

Description complète

Détails bibliographiques

Auteurs principaux:	Katharina Otte, Kai Zhao, Madita Braun, Andreas Neubauer, Hartmann Raifer, Frederik Helmprobst, Felipe Ovalle Barrera, Christopher Nimsky, Jörg W. Bartsch, Tillmann Rusch
Format:	Artigo
Langue:	Inglês
Publié:	MDPI AG 2022-08-01
Collection:	Biomedicines
Sujets:	GBM Eltanexor SINE XPO1 temozolomide radiosensitivity
Accès en ligne:	https://www.mdpi.com/2227-9059/10/9/2145
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!